កិច្ចព្រមព្រៀង Globus Medical-NuVasive ដើម្បីពន្លឿនយុទ្ធសាស្ត្រសកលភាវូបនីយកម្ម គោលដៅទីផ្សារសាច់ដុំ $50B

• Globus Medical Inc (NYSE: GMED) និង NuVasive Inc (ផ្សារហ៊ុន NASDAQ: NUVA) have agreed to combine in an all-stock transaction, bringing together two technology companies to accelerate globalization strategy to target the $50 billion musculoskeletal market.

• Together, Globus Medical and NuVasive will have a presence in more than 50 countries with more than 5,000 employees.

• Each NuVasive share will be exchanged for 0.75 of Globus Medical share.

• NuVasive has an implied value of $57.72/share and an equity value of $3.1 billion.

• Following the close of the transaction in mid-2023, NuVasive shareholders will own approximately 28% of the combined company, and Globus Medical shareholders will own approximately 72% on a fully diluted basis.

• The company will leverage Globus Medical’s financial rigor and discipline as it aims to deliver a mid-30-percent EBITDA profile over the next three years, which includes approximately $170 million in identified cost synergies.

• The company will have an eleven-member board composed of all eight directors from Globus Medical’s board and three from NuVasive’s board.

• David Paul, Chairman of the Globus Medical board, will serve as Chairman of the combined company’s board.

• Dan Scavilla will serve as CEO, and Keith Pfeil, CFO of Globus Medical, will serve as CFO of the combined company.

• For FY22, Globus Medical announces preliminary 2022 net sales growth of 6.8% Y/Y as reported, 8.2% constant currency.

• NuVasive announces preliminary 2022 net sales growth of 5.5% as reported, 8.5% constant currency, as compared to net sales of $1,139.0 million for the full year 2021.

• For FY23, Globus Medical expects net sales growth of 7%ꟷ8% constant currency, and NuVasive expects 2023 net sales growth of 6%ꟷ8% constant currency.

• សកម្មភាពតម្លៃ: GMED shares are down 15.60% at $64.97, and NUVA shares are up 2.66% at $47 during the premarket session on the last check Thursday.

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

រឿងរ៉ាវនៅតែបន្ត

អត្ថបទ​នេះ កិច្ចព្រមព្រៀង Globus Medical-NuVasive ដើម្បីពន្លឿនយុទ្ធសាស្ត្រសកលភាវូបនីយកម្ម គោលដៅទីផ្សារសាច់ដុំ $50B ដើមដំបូងបានបង្ហាញខ្លួន benzinga.com

.

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។